Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...

Alpha Cognition's ZUNVEYL targets Alzheimer's with improved tolerability over existing galantamine therapies. Read why I rate ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

Eli Lilly & Company (NYSE: LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

TORONTO -- The antiviral agent valacyclovir demonstrated no benefit in early Alzheimer's disease, the phase II VALAD trial ...

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.